Kennedy Investment Group Invests $1 Million in Novo Nordisk A/S $NVO

Kennedy Investment Group purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 19,672 shares of the company’s stock, valued at approximately $1,001,000.

A number of other institutional investors also recently modified their holdings of the business. Guerra Advisors Inc bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at $25,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth $28,000. Maseco LLP bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $29,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk expanded its obesity pipeline with updates on the AMAZE 12 Phase 3 trial and a new cagrilintide study, reinforcing its push to maintain leadership beyond current blockbuster products. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Positive Sentiment: The company also announced a share repurchase program, which can support earnings per share and signals management confidence in Novo Nordisk’s cash generation. Novo Nordisk A-S share repurchase programme
• Neutral Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Novo Nordisk, adding a modestly constructive analyst note but not a major catalyst on its own.
• Neutral Sentiment: News coverage highlighted Novo Nordisk’s plan to push obesity treatments globally, especially outside the U.S., where the company sees a major growth opportunity. Novo Nordisk’s next obesity battlefront: Winning beyond America
• Negative Sentiment: Investors remain focused on intensifying competition from Eli Lilly and other GLP-1 rivals, with articles noting the race to launch obesity pills globally and the risk of new entrants pressuring Novo Nordisk’s market share. GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
• Negative Sentiment: Citi tracking showed Wegovy pill prescriptions slipped week over week, even though the drug still leads competitors, suggesting momentum is strong but not uninterrupted. Novo Nordisk’s Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $44.24 on Wednesday. The company’s fifty day moving average price is $39.95 and its 200-day moving average price is $46.54. The firm has a market capitalization of $197.52 billion, a price-to-earnings ratio of 10.38, a PEG ratio of 3.94 and a beta of 0.77. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price for the company. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.